Cart
sales@molnova.com
KDM2B-IN-2
CAS No. 1965248-01-4
KDM2B-IN-2( —— )
Catalog No. M35115 CAS No. 1965248-01-4
KDM2B-IN-2 is a potent histone demethylase (kdm2b) inhibitor.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 91 | Get Quote |
|
| 5MG | 140 | Get Quote |
|
| 10MG | 217 | Get Quote |
|
| 25MG | 394 | Get Quote |
|
| 50MG | 588 | Get Quote |
|
| 100MG | 801 | Get Quote |
|
| 500MG | 1647 | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameKDM2B-IN-2
-
NoteResearch use only, not for human use.
-
Brief DescriptionKDM2B-IN-2 is a potent histone demethylase (kdm2b) inhibitor.
-
DescriptionKDM2B-IN-2, a potent histone demethylase (kdm2b) inhibitor with an IC50 of 0.021 μM in a KDM2B TR-FRET assay. KDM2B-IN-2 can be used for hyperproliferative diseases research.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayChromatin/Epigenetic
-
TargetHistone Demethylase
-
RecptorHistone Demethylase
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1965248-01-4
-
Formula Weight430.59
-
Molecular FormulaC21H26N4O2S2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 31.25 mg/mL (72.57 mM; ultrasonic and heat to 80°C)
-
SMILESO=S(=O)(N1CCN=C1N1CCN(CC1)C1CCC1)c1ccc(cc1)-c1ccsc1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Brian K. Albrecht, et al. 4,5-dihydroimidazole derivatives and their use as histone demethylase (kdm2b) inhibitors. Patent WO2016112251A1.
molnova catalog
related products
-
SETDB1-TTD-IN-1
SETDB1-TTD-IN-1 is a potent, selective and endogenous binder competitive inhibitor of SETDB1-TTD with a Kd of 88 nM.
-
DDP-38003 dihydrochl...
DDP-38003 is an novel, orally available inhibitor of histone lysine-specific demethylase 1A (KDM1A/LSD1) with IC50 of 84 nM.
-
C 21
Selective protein arginine methyltransferase 1 (PRMT1) inhibitor (IC50 = 1.8 μM). Exhibits five-fold selectivity for PRMT1 over PRMT6 and >250-fold selectivity over PRMT3 and CARM1.
